Pharmacotherapy for dyslipidaemia–current therapies and future agents

H Bays, EA Stein - Expert opinion on pharmacotherapy, 2003 - Taylor & Francis
Current lipid-altering agents that lower low density lipoprotein cholesterol (LDL-C) primarily
through increased hepatic LDL receptor activity include statins, bile acid sequestrants/resins …

Novel agents to manage dyslipidemias and impact atherosclerosis

S Nachimuthu, P Raggi - Cardiovascular & Haematological …, 2006 - ingentaconnect.com
Strong epidemiological evidence linked elevated levels of low-density lipoprotein
cholesterol (LDL-C) to risk of atherosclerotic heart disease. As a consequence, LDL-C …

Novel agents for managing dyslipidaemia

AJ Jenkins, JD Best - Expert Opinion on Investigational Drugs, 2001 - Taylor & Francis
An elevated low-density lipoprotein (LDL) cholesterol level is a strong predictor of coronary
heart disease (CHD) risk. Over the past seven years, equally strong evidence has …

Lifibrol as a Model Compound for a Novel Lipid-Lowering Mechanism of Action

HK Berthold, T Sudhop… - Journal of …, 2010 - journals.sagepub.com
Lifibrol is a potent lipid-lowering drug with an unknown mechanism of action. We
investigated its effects on lipoprotein and sterol metabolism in normocholesterolemic male …

[PDF][PDF] In-vivo-Kinetik der Apolipoproteine B-100 und AI bei Patienten mit Hyperlipidämie unter dem Einfluss des Lipidsenkers Lifibrol

AM Sattler - 2002 - archiv.ub.uni-marburg.de
Die Atherosklerose und ihre Folgeschäden sind trotz aller Fortschritte in der Diagnostik und
Therapie weiterhin die Haupttodesursachen in den westlichen Industrienationen [101]. Die …